Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 23:10:2325-33.
doi: 10.2147/IJN.S75174. eCollection 2015.

Water-soluble L-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma

Shuyan Liang  1 , Qing Zhou  1 , Min Wang  2 , Yanhong Zhu  1 , Qingzhi Wu  2 , Xiangliang Yang  1
Affiliations

Water-soluble L-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma

Shuyan Liang et al. Int J Nanomedicine. .

Abstract

Nanoparticles (NPs) are advantageous for the delivery of diagnosis agents to brain tumors. In this study, we attempted to develop an L-cysteine coated FePt (FePt-Cys) NP as MRI/CT imaging contrast agent for the diagnosis of malignant gliomas. FePt-Cys NPs were synthesized through a co-reduction route, which was characterized by transmission electron microscopy, high-resolution transmission electron microscopy, powder X-ray diffraction, Fourier transform infrared spectroscopy, and dynamic light scattering. The MRI and CT imaging ability of FePt-Cys NPs was evaluated using different gliomas cells (C6, SGH44, U251) as the model. Furthermore, the biocompatibility of the as-synthesized FePt-Cys NPs was evaluated using three different cell lines (ECV304, L929, and HEK293) as the model. The results showed that FePt-Cys NPs displayed excellent biocompatibility and good MRI/CT imaging ability, thereby indicating promising potential as a dual MRI/CT contrast agent for the diagnosis of brain malignant gliomas.

Keywords: CT; MRI; glioma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TEM (A) and HRTEM (B) images of as-synthesized FePt-Cys NPs. Note: The arrows in the inset of B indicate the distance between the two adjacent planes. Abbreviations: d, interplanar distance; FePt-Cys, l-cysteine coated FePt; HRTEM, high-resolution TEM; NPs, nanoparticles; TEM, transmission electron microscopy.
Figure 2
Figure 2
XRD pattern of FePt-Cys NPs. Abbreviations: FePt-Cys, l-cysteine coated FePt; NPs, nanoparticles; XRD, powder X-ray diffraction.
Figure 3
Figure 3
FT-IR spectra of pure Cys molecules (A) and FePt-Cys NPs (B). Abbreviations: Cys, l-cysteine; FePt-Cys, l-cysteine coated FePt; FT-IR, Fourier transform infrared spectroscopy; NPs, nanoparticles.
Figure 4
Figure 4
Size distributions of FePt-Cys dispersed in different media for different times. Notes: (A) Size distribution of FePt-Cys NPs dispersed in H2O. (B) Size changes of FePt-Cys NPs in H2O and cell culture media (DMEM +10% FBS) in the period of 7 days. Abbreviations: DMEM, Dulbecco’s Modified Eagle’s Medium; FBS, fetal bovine serum; FePt-Cys, l-cysteine coated FePt; NPs, nanoparticles; PDI, polydispersity index.
Figure 5
Figure 5
Magnetization hysteresis loop of the as-synthesized FePt-Cys NPs. Abbreviations: FePt-Cys, l-cysteine coated FePt; NPs, nanoparticles.
Figure 6
Figure 6
MR contrast imaging of FePt-Cys NPs. Notes: (A) The T2-weighted MR images of FePt-Cys NPs at different Fe concentrations. (B) T2 relaxation rates (1/T2) plotted against the Fe concentration of FePt-Cys NPs. Abbreviations: FePt-Cys, l-cysteine coated FePt; MR, magnetic resonance; NPs, nanoparticles; r2, relaxation rate.
Figure 7
Figure 7
CT imaging evaluation of different samples. Notes: (A) The CT images of iohexol at different iodine concentrations; (B) The CT images of FePt-Cys NPs at different Pt concentrations; (C) The signal intensity of iohexol plotted against the concentration of iodine; (D) The signal intensity of FePt-Cys NPs plotted against the concentration of Pt. Abbreviations: CT, computed tomography; FePt-Cys, l-cysteine coated FePt; NPs, nanoparticles.
Figure 8
Figure 8
Imaging of different gliomas cells (C6, SGH44, and U251) treated with FePt-Cys NPs. Notes: (A) MR imaging of different gliomas cells at different Fe concentrations; (B) CT imaging of different gliomas cells at different Pt concentrations. Abbreviations: CT, computed tomography; FePt-Cys, l-cysteine coated FePt; MR, magnetic resonance; NPs, nanoparticles.
Figure 9
Figure 9
Viabilities of different cell lines treated with FePt-Cys NPs at different Fe concentrations and time intervals. Notes: (A) ECV 304 cells; (B) L929 cells; and (C) HEK293 cells. Abbreviations: FePt-Cys, l-cysteine coated FePt; NPs, nanoparticles.
See this image and copyright information in PMC

References

    1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–509. - PubMed
    1. Orringer DA, Koo YE, Chen T, Kopelman R, Sagher O, Philbert MA. Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther. 2009;85(5):531–534. - PMC - PubMed
    1. Rozhkova EA. Nanoscale materials for tackling brain cancer: recent progress and outlook. Adv Mater. 2011;23(24):H136–H150. - PubMed
    1. Li M, Deng H, Peng H, Wang Q. Functional nanoparticles in targeting gliomas diagnosis and therapies. J Nanosci Nanotechnol. 2014;14(1):415–432. - PubMed
    1. Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS. Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev. 2014;66:42–57. - PMC - PubMed

Publication types